SAN DIEGO—Cytiva has launched its Sefia next-generation manufacturing platform, with the goal of helping drug developers and larger healthcare providers accelerate their production of chimeric antigen ...
From lab bench to publication: integrity travels with you In research, digital images, including gel electrophoresis and ...
The MarketWatch News Department was not involved in the creation of this content. -- Collaboration combines Nuclera's eProtein Discovery System, which accelerates protein expression, purification and ...
Cytiva, a Massachusetts-based research and biopharma manufacturing specialist, has opened the doors to its production facility in Cardiff, Wales. The 11,000-square-meter Welsh facility is already ...
Cytiva’s acquisition of CEVEC Pharmaceuticals strengthens the company’s cell line development and biomanufacturing capabilities. Cytiva has acquired CEVEC Pharmaceuticals, a Germany-based provider of ...
Cytiva and LevitasBio signed an agreement to jointly work on delivering an advanced single-cell workflow for genomics researchers in academia and industry. The collaboration marks a significant ...
HHS said it will give $31 million to Massachusetts pharmaceutical manufacturer Cytiva to scale up its production of materials needed to produce COVID-19 vaccines, the department announced Oct. 13. The ...
· Collaboration will help reduce stable cell line development timelines in AAV genomic medicine development and ultimately also shorten development timeline to clinic Cytiva, a Danaher company and a ...
Cambridge, UK and Marlborough, MA, 28 May 2025: Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ System, has announced a ...
Collaboration combines Nuclera’s eProtein Discovery System, which accelerates protein expression, purification and optimization, with Cytiva’s Biacore SPR system, which characterizes molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results